The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis

Filipović, Saša R.; Drulović, Jelena; Stojsavljević, Nebojša; Lević, Z

doi:10.1016/s0022-510x(97)00159-7

Cited by 45 publications

(25 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No significant changes are reported after 1 or 4 years of interferon h-1b therapy [27,28]; conversely significantly improved P300 latency is described after short term high dose of methylprednisolone [29].…”

Section: Erps (P300) and Msmentioning

confidence: 93%

Cognitive impairment and neurophysiological correlates in MS

Magnano

Aiello

Piras

2006

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Section: Erps (P300) and Msmentioning

confidence: 93%

Cognitive impairment and neurophysiological correlates in MS

Magnano

Aiello

Piras

2006

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…Overall, the four trials of MP (total n = 140) and two trials of ACTH (total n = 237) supported similar benefits of MP and ACTH in acute MS exacerbations [Durelli et al 1985;Filipovic et al 1997;Miller et al 1961;Milligan et al 1987;Rose et al 1970;Sellebjerg et al 1998]. In this review, insomnia was included in the category of psychiatric disturbances.…”

Section: Discussionmentioning

confidence: 87%

Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series

Murray¹,

Woo²

2015

Ther Adv Neurol Disord

View full text Add to dashboard Cite

The elevated prevalence of neuropsychiatric symptoms and disorders among patients with multiple sclerosis (MS) is well recognized, as are potential neuropsychiatric side effects of treatment with corticosteroids. Both methylprednisolone (MP) and repository corticotropin injection (HP Acthar® gel) have demonstrated efficacy in reducing short-term disability after exacerbations of MS. Although historical data are limited, repository corticotropin injection has not generally been associated with detrimental neuropsychiatric effects. We describe six cases of patients with relapsing-remitting MS who had previously experienced detrimental mood changes with MP treatment. Some of these patients had previous histories of mood disorders or other neuropsychiatric symptoms prior to MS diagnosis. All six patients were subsequently treated with repository corticotropin injection for MS exacerbations and each demonstrated improvements in MS symptoms. This clinical experience suggests that repository corticotropin injection should be considered as an alternative for patients who do not tolerate corticosteroids or have difficulties associated with intravenous medication. Furthermore, the rate of neuropsychiatric side effects observed in these patients was low. These observations support repository corticotropin injection as a viable alternative for the treatment of acute exacerbations of MS, particularly in patients who have a history of neuropsychiatric disorders or symptoms either independently or in response to MP treatment. In reviewing both the published data and our own clinical experience regarding potential neuropsychiatric adverse events with treatment for MS exacerbations, we hope to stimulate further research into the potential efficacy and safety of repository corticotropin injection among patients with some form of neuropsychiatric complications that must be considered when establishing a treatment plan for MS.

show abstract

“…Başlangıç etkisi hızlıdır, genellikle ilk haftada başlar. Günümüzde kısa süreli yüksek doz MP tedavisinin faydaları kesin kanıtlanmıştır (12). Yüksek doz I.V.…”

Section: Discussionunclassified

“…GC'lerin MS'de ilk görülen etkisi kan beyin bariyeri bozulmasını önlemektir. Antiödematöz etkisi bir yana bırakıldığında kan beyin bariyeri restorasyonu, steroid hormonların direk ve hızlı membran etkileri ile oluşur (12). GC'ler doz bağımlı etki etmektedirler.…”

Section: Discussionunclassified

Multiple Sklerozlu Hastada Spastisite ile Karışabilecek Femur Başı Avasküler Nekrozu: Olgu Sunumu

Baygutalp¹,

Işık²,

Şenel³

2014

tod

View full text Add to dashboard Cite

SummaryMultiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS). Disease is often characterized by attacks and remissions. The lesions present various symptoms according to their locations in the CNS. The treatment can be divided into three categories as attack treatment, prophylactic therapy and symptomatic treatment. Glucocorticoids (GC) are used in acute attacks of MS usually in intravenous pulse form for 3-10 days several times in a year and they accelerate the remission of attacks. GC has various positive and negative effects on the musculoskeletal system. Avascular necrosis (osteonecrosis) is a common complication of GC using. GC-induced avascular necrosis is frequently seen in femoral head. GC-induced femoral head avascular necrosis (FHAVN) may occur in patients with MS. FHAVN may be asymptomatic and painless or may cause pain and limitations in the hips. Since hip pain and limitations can be seen in MS patients due to spasticity, FHAVN should be absolutely considered and ruled out in differential diagnosis. In this article, a FHAVN case developed due to high-dose GC using for several times a year in a patient while being followed-up for MS was presented, and the association of these two diseases was discussed in the light of current literature. The aim of this case report is to point out the importance of ruling FHAVN by magnetic resonance imaging (MRI) in MS patients even they have normal direct radiography findings.

show abstract

The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis

Cited by 45 publications

References 49 publications

Cognitive impairment and neurophysiological correlates in MS

Cognitive impairment and neurophysiological correlates in MS

Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series

Multiple Sklerozlu Hastada Spastisite ile Karışabilecek Femur Başı Avasküler Nekrozu: Olgu Sunumu

Contact Info

Product

Resources

About